For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,953,000 | -960,000* | 2,789,000 | - |
| General, administrative and other | 2,115,000 | 4,175,000* | 2,249,000 | - |
| Total operating expenses | 5,068,000 | 3,215,000 | 5,038,000 | - |
| Loss from operations | -5,068,000 | -3,215,000* | -5,038,000 | - |
| Change in fair value of warrant liability | - | 0* | - | 0 |
| Change in fair value of forward contract liability | - | 0* | - | - |
| Change in fair value of sepa put option liability | 54,000 | 253,000* | 33,000 | - |
| Change in fair value of convertible debt | 0 | 765,000* | -846,000 | - |
| Commitment fee expenses | - | 0* | - | 0 |
| Placement agent and tail fee expenses | - | 0* | - | - |
| Other expense | -2,000 | -619,000* | 0 | 0 |
| Gain on termination of warrant and commitment fee liabilities | - | 0* | - | - |
| Interest income | 20,000 | 28,000* | 73,000 | - |
| Interest expense | 4,000 | 204,000* | 0 | 0 |
| Total other income/(expense) | 68,000 | 223,000* | -740,000 | - |
| Net loss | -5,000,000 | -2,992,000 | -5,778,000 | -4,658,000 |
| Net income (loss) attributable to common stockholders | - | - | - | -4,658,000 |
| Basic EPS | -1.33 | -0.057 | -0.13 | -0.12 |
| Diluted EPS | -1.33 | -0.057 | -0.13 | -0.12 |
| Basic Average Shares | 3,772,930 | 52,273,748 | 43,072,542 | 38,635,264 |
| Diluted Average Shares | 3,772,930 | 52,273,748 | 43,072,542 | 38,635,264 |
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)